Analysts Issue Forecasts for Nuvectis Pharma FY2027 Earnings

Key Points

• Roth Capital has lowered its FY2027 earnings estimate for Nuvectis Pharma to $1.03 per share, slightly down from a previous forecast of $1.06.
• HC Wainwright reiterated a "buy" rating for Nuvectis Pharma, increasing its price target from $11.00 to $15.00.
• Insider Marlio Charles Mosseri purchased 28,043 shares of Nuvectis Pharma, raising their total ownership to about $23.96 million.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Roth Capital dropped their FY2027 EPS estimates for Nuvectis Pharma in a report released on Thursday, July 31st. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $1.03 for the year, down from their prior forecast of $1.06. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's FY2028 earnings at $2.40 EPS and FY2029 earnings at $3.31 EPS.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05).

Several other research firms have also recently weighed in on NVCT. HC Wainwright decreased their price objective on shares of Nuvectis Pharma from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Monday. Wall Street Zen cut shares of Nuvectis Pharma from a "hold" rating to a "sell" rating in a research report on Sunday, June 29th.

Nuvectis Pharma Price Performance

NVCT stock traded down $0.41 during trading on Friday, reaching $6.88. 236,040 shares of the company were exchanged, compared to its average volume of 145,638. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $11.80. The company has a 50-day moving average of $8.14 and a two-hundred day moving average of $8.26. The company has a market capitalization of $143.79 million, a price-to-earnings ratio of -6.02 and a beta of -0.26.

Insider Activity

In other news, major shareholder Marlio Charles Mosseri acquired 28,043 shares of Nuvectis Pharma stock in a transaction on Wednesday, June 18th. The stock was acquired at an average cost of $8.05 per share, for a total transaction of $225,746.15. Following the purchase, the insider owned 2,976,203 shares in the company, valued at $23,958,434.15. This trade represents a 0.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have bought 62,862 shares of company stock valued at $508,887. 30.52% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nuvectis Pharma

Several large investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new position in shares of Nuvectis Pharma in the fourth quarter worth about $34,000. Blue Zone Wealth Advisors LLC acquired a new position in shares of Nuvectis Pharma during the first quarter valued at about $102,000. Squarepoint Ops LLC acquired a new position in shares of Nuvectis Pharma during the fourth quarter valued at about $103,000. Northern Trust Corp increased its holdings in shares of Nuvectis Pharma by 68.7% during the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company's stock valued at $139,000 after acquiring an additional 10,472 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in Nuvectis Pharma in the 1st quarter worth approximately $321,000. Hedge funds and other institutional investors own 96.77% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.